Phio reports $13.0 million in cash as of June 30, 2026, down from $21.0 million at year-end 2025, extending runway into late 2027.
Phio Pharmaceuticals reported a Q2 GAAP loss of $0.36 per share, matching expectations. The company’s cash position declined to $13.0 million as of June 30, 2026, from $21.0 million at December 31, 2025.
The biotech firm continues to prioritize development of PH-762 while managing administrative expenses. It expects current cash reserves to support operations into the second half of 2027, providing a clear runway for near-term projects.
No immediate market reaction was disclosed in the release.